Literature DB >> 24751445

Hot spot-based design of small-molecule inhibitors for protein-protein interactions.

Wenxing Guo1, John A Wisniewski1, Haitao Ji2.   

Abstract

Protein-protein interactions (PPIs) are important targets for the development of chemical probes and therapeutic agents. From the initial discovery of the existence of hot spots at PPI interfaces, it has been proposed that hot spots might provide the key for developing small-molecule PPI inhibitors. However, there has been no review on the ways in which the knowledge of hot spots can be used to achieve inhibitor design, nor critical examination of successful examples. This Digest discusses the characteristics of hot spots and the identification of druggable hot spot pockets. An analysis of four examples of hot spot-based design reveals the importance of this strategy in discovering potent and selective PPI inhibitors. A general procedure for hot spot-based design of PPI inhibitors is outlined.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Keywords:  Hot spots; Inhibitor; Protein–protein interactions; Rational design; Selectivity

Mesh:

Substances:

Year:  2014        PMID: 24751445     DOI: 10.1016/j.bmcl.2014.03.095

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  35 in total

1.  Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome.

Authors:  Alicia Mansilla; Antonio Chaves-Sanjuan; Nuria E Campillo; Ourania Semelidou; Loreto Martínez-González; Lourdes Infantes; Juana María González-Rubio; Carmen Gil; Santiago Conde; Efthimios M C Skoulakis; Alberto Ferrús; Ana Martínez; María José Sánchez-Barrena
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-24       Impact factor: 11.205

Review 2.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

3.  Saturation scanning of ubiquitin variants reveals a common hot spot for binding to USP2 and USP21.

Authors:  Isabel Leung; Ayelet Dekel; Julia M Shifman; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-19       Impact factor: 11.205

Review 4.  Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery.

Authors:  Marcus J C Long; Dziyana Hnedzko; Bo Kyoung Kim; Yimon Aye
Journal:  Chembiochem       Date:  2019-04-01       Impact factor: 3.164

Review 5.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

Review 6.  Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases.

Authors:  Sabrina Fechtner; David A Fox; Salahuddin Ahmed
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580

7.  Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.

Authors:  David Hymel; Robert A Grant; Kohei Tsuji; Michael B Yaffe; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2018-08-19       Impact factor: 2.823

8.  Targeting the Side-Chain Convergence of Hydrophobic α-Helical Hot Spots To Design Small-Molecule Mimetics: Key Binding Features for i, i + 3, and i + 7.

Authors:  Zhen Wang; Haitao Ji
Journal:  J Med Chem       Date:  2019-10-22       Impact factor: 7.446

Review 9.  Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

Authors:  Sitanshu S Singh; Seetharama D Jois
Journal:  Adv Protein Chem Struct Biol       Date:  2017-10-06       Impact factor: 3.507

10.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.